Company profile for Sentinel BioTherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sentinel BioTherapeutics is a Houston-based clinical-stage biotech spun out from RBL LLC. We’re pioneering localized cytokine immunotherapies using encapsulated cell-based platforms that deliver interleukin-2 directly to solid tumors—aiming to enhance immune checkpoint therapies while minimizing toxicity. With Phase I data showing dose-dependent T cell activation, Fast Track and Orphan Disease designations, and Phase II tr...
Sentinel BioTherapeutics is a Houston-based clinical-stage biotech spun out from RBL LLC. We’re pioneering localized cytokine immunotherapies using encapsulated cell-based platforms that deliver interleukin-2 directly to solid tumors—aiming to enhance immune checkpoint therapies while minimizing toxicity. With Phase I data showing dose-dependent T cell activation, Fast Track and Orphan Disease designations, and Phase II trials in progress, our mission is to revolutionize treatment for hard-to-treat cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Boulevard, D343 Biology Department, New York, NY 11367
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/sentinel-biotherapeutics-appoints-dr-zelanna-goldberg-to-board-of-directors-and-as-chair-of-clinical-advisory-board-302613721.html

PR NEWSWIRE BIO
13 Nov 2025

https://www.prnewswire.com/news-releases/made-scientific-and-sentinel-biotherapeutics-announce-strategic-manufacturing-partnership-to-advance-ph-iii-allogeneic-epp-encapsulated-cell-therapy-program-302505617.html

PR NEWSWIRE
15 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty